Skip to main content
Equibles

3349 · COSMOS Pharmaceutical Corporation · Financials

Use 3349 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 3349.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
6,353 JPY +117 (+1.88%) At close · Nov 12
Rebalance outlook locked
Market Cap
503.52B JPY
Shares
79.26M
Volume · Nov 12 362.5K Avg daily vol (3M) 466.43K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
1.1T +8.7%
FY2026 Revenue FY2022–FY2026
Net Income
32.05B +3.4%
FY2026 Net Income FY2022–FY2026
Gross Margin
20.89% -0.2pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
3.85% -0.1pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
58.79B +12.1%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 1.1T 1.01T 964.99B 827.7B 755.41B
JPY 869.9B 798.11B 776.68B 658.98B 603.97B
JPY 229.68B 213.28B 188.31B 168.72B 151.45B
JPY 42.35B 40.4B 31.5B 30.13B 29.8B
JPY 44.22B 42.37B 33.72B 32.77B 33.05B
JPY 12.17B 11.39B 9.27B 8.98B 9.89B
JPY 32.05B 30.98B 24.45B 23.8B 23.16B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 22.09B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.